Taiwan Life Insurance Co (台灣人壽保險) is to stop selling insurance savings plans that promise high returns within one year, company president Tony Chuang (莊中慶) said on Thursday.
The move came after the Financial Supervisory Commission on Wednesday announced that it would enhance reviews of insurance savings plans and lower the ratio of death benefits, which would discourage insurers from selling savings plans.
“The commission’s new regulations will affect insurers’ marketing strategies, but we agree that insurance is not intended for wealth management,” Chuang told reporters on the sidelines of an event in Taipei.
Taiwan Life stopped selling single-premium insurance savings plans in July last year.
Chuang said the products had forced the company to prepare a larger special reserve after adopting the International Financial Reporting Standards 17.
The insurer is to first stop sales of savings plans that are subject to a six-year payment requirement and would gradually suspend the sale of other plans that promise high returns, Chuang said.
Taiwan Life is not worried about the effect on its premium income after the plans are ended, he said.
The company would set a long-term plan to achieve stable profit growth, Chuang added.
The company’s equity-to-asset ratio has climbed to 5 percent after it injected NT$10 billion (US$317.26 million) in new funds last month, he said.
Insurers whose equity-to-asset ratio is lower than 3 percent must increase their capital, the commission said on Wednesday.
Separately, local life insurers reported foreign-exchange gains of NT$66.7 billion in the first four months of the year.
However, those gains were offset by cumulative hedging losses of NT$135.8 billion over the period, which saw combined pretax profit plunge 10.9 percent annually to NT$47.6 billion, Insurance Bureau data showed.
Taiwan and China are to build more new high-volume semiconductor fabrication plants this year and next year than any other country, together contributing more than half of all new fabs in the world by constructing eight each, SEMI said in a quarterly report yesterday. Global chipmakers are to start building 19 new high-volume fabs by the end of this year and another 10 next year to meet accelerating demand for chips from the communications, computing, healthcare, online services and automotive sectors, SEMI, an association that represents the global semiconductor sector, said in its quarterly report. “Equipment spending for these 29 fabs is
Major PC vendors expect a shortage of key components to last another 12 months until the second quarter of next year, when PC demand wanes after two years of robust expansion, a UBS analyst said yesterday. Concern has risen among investors that PC demand could weaken as the US and European economies reopen from COVID-19 lockdowns and gradually return to in-person business activities. At the annual Taiwan Conference that began on Monday, UBS analysts said they had similar discussions with companies in PC supply chains, and the feedback from major PC vendors indicated that demand remained quite strong on the back of
QUICK CHANGE: After a prolonged drought, the Water Resources Agency said it is preparing for potential floods from intense rainfall this week The Ministry of Economic Affairs yesterday announced that it was easing water restrictions in several regions, thanks to rainfall over the past few days. The water supply alert level has been downgraded from “orange” to “yellow” for Taoyuan and Hsinchu and Miaoli counties, and from “orange” to “green” for Tainan and Chiayi County, the ministry said. Only Taichung remains under “orange” alert, with round-the-clock decreased water pressure, it said. A combination of water management measures and considerable plum rains and tropical showers has seen reservoirs significantly replenished across the nation, Minister of Economic Affairs Wang Mei-hua (王美花) said. Just weeks ago water levels
OPPORTUNITY: The company aims to sell its product soon, as enterovirus vaccines are not available anywhere but China, where firms are only marketing their vaccines locally Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations. The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday. Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said. The company enrolled its first participant for